Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,405 across all filing types
Latest filing 2025-02-13 Regulatory Filings
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings
2025-02-13 English
Communiqué de presse : Mise à jour sur l’étude clinique de phase III du vaccin contre les souches E. coli responsables d'infections extra-intestinales
Regulatory Filings Classification · 99% confidence The document is titled "Communiqué de presse" (Press Release) and announces the termination of a Phase III clinical trial (E.mbrace) for a vaccine candidate due to insufficient efficacy, while noting no safety signals. It includes quotes from management, details about the trial, financial impact (impairment charge), and standard forward-looking statements referencing filings like the Universal Registration Document (AMF) and Form 20-F (SEC). This format—a formal announcement of significant business/R&D news, often including financial consequences—is characteristic of an Earnings Release (ER) or a general regulatory announcement. Since it is a press release announcing key operational and financial updates (trial failure and associated write-down), it aligns best with the 'Earnings Release' (ER) category, which covers initial announcements of periodical/significant results, even if not strictly quarterly earnings. It is not a full 10-K, a transcript (CT), or a specific capital action (CAP/SHA). Given the focus on the outcome of a major R&D program and the immediate financial impact, ER is the most appropriate fit among the provided options, although it could also be considered a Regulatory Filing (RNS) if ER was too narrow. However, the structure strongly suggests an ER.
2025-02-13 French
Press Release: Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study
Regulatory Filings Classification · 95% confidence The document is explicitly titled 'Press Release' and announces the discontinuation of a Phase 3 clinical study due to insufficient efficacy findings from an independent interim analysis. It details the financial impact (impairment charge recorded in Q4 2024 IFRS results) and mentions that this adjustment will be included in Sanofi's Form 20-F for 2024. This structure—a timely announcement of a significant business/clinical event with immediate financial consequences, released as a press release—is characteristic of an Earnings Release (ER) or a general regulatory announcement. Since it is not a full financial report (like 10-K or IR), nor a transcript (CT), nor a specific management discussion (MDA), and it focuses on a major operational/clinical update that has immediate financial reporting implications, the best fit among the provided options is 'Earnings Release' (ER), as these releases often contain key operational updates alongside preliminary financial impacts, or 'Regulatory Filings' (RNS) as a general announcement. Given the focus on the clinical trial outcome and the immediate recording of an impairment charge, it functions as a major operational update often bundled with earnings news. However, since it is not explicitly stating quarterly/periodical financial results (like revenue/net income figures for the period, although EPS impact is mentioned), and it is a specific operational update, 'Regulatory Filings' (RNS) serves as a strong general category for significant, non-standard announcements. Comparing ER (initial announcement of periodical financial results, key highlights only) vs RNS (general regulatory announcements and fallback), this is a highly specific operational update that impacts financials. If this were released alongside the Q4 results, it would be part of the ER package. As a standalone press release detailing a major R&D event and its financial consequence, RNS is the most appropriate fallback for a specific event announcement that isn't a core financial report or a standard earnings summary. I will classify it as RNS as it is a significant, non-standard regulatory/operational announcement.
2025-02-13 English
Franchissement de seuil
Major Shareholding Notification Classification · 100% confidence The document is an official notice from the Autorité des marchés financiers (AMF) regarding a 'Déclaration de franchissement de seuil' (threshold crossing declaration) for the company Sanofi. This specifically details a change in major shareholding ownership by L'Oréal. This fits the definition of a Major Shareholding Notification (MRQ).
2025-02-11 French
Sanofi: Disclosure of trading in own shares
Transaction in Own Shares Classification · 100% confidence The document is explicitly titled 'Disclosure of trading in own shares' and contains tables detailing daily share repurchase volumes, prices, and transaction dates. This aligns perfectly with the definition for 'Transaction in Own Shares' (POS), which covers reports of companies buying back their own shares.
2025-02-10 English
Sanofi : Déclaration des transactions sur actions propres
Transaction in Own Shares Classification · 100% confidence The document is titled 'Déclaration des transactions sur actions propres' (Declaration of transactions on own shares) and provides a detailed table of share repurchase transactions conducted by Sanofi. This aligns perfectly with the definition for 'Transaction in Own Shares' (POS), which covers reports of companies buying back their own shares.
2025-02-10 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.